Clinical Trial Update: Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC). [Phase 2]

View source ↗

Summary

Phase 2 trial investigating neoadjuvant and adjuvant tiragolumab plus atezolizumab in newly diagnosed PD-L1 CPS-positive resectable stage 3-4 oral cavity squamo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Oral Cavity Squamous Cell Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Tiragolumab (tiragolumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma | Phase 2 | Status: RECRUITING